Featured Research

from universities, journals, and other organizations

Drug Brings Relief For Many IBS Patients Who Experience Constipation

Date:
May 20, 2008
Source:
University of Michigan Health System
Summary:
Many patients may soon find relief from the bloating, cramping, abdominal pain and constipation associated with irritable bowel syndrome. AMITIZA was just approved by the FDA for use in women with IBS plus constipation, thanks to new research that demonstrated the safety and efficacy of the drug for treatment of IBS-C.

Many patients may soon find relief from the bloating, cramping, abdominal pain and constipation associated with irritable bowel syndrome, or IBS.

Lubiprostone, known by the brand name AMITIZA®, was just approved by the U.S. Food and Drug Administration for use in women with IBS plus constipation, thanks in part to University of Michigan Health System research that demonstrated the safety and efficacy of the drug for treatment of IBS-C.

Led by U-M gastroenterologist William D. Chey, M.D., the studies show that lubiprostone significantly improves all of the symptoms associated with IBS-C in many women.

Results from these studies will be presented on May 18 and May 19 at Digestive Diseases Week in San Diego.

"We found that individuals who were treated with AMITIZA were nearly twice as likely to experience improvement in their IBS symptoms compared to individuals who were treated with placebo," says Chey, director of the Gastrointestinal Physiology Laboratory and professor of internal medicine at the U-M Medical School. "Right now, it is the only FDA-approved treatment available that addresses the entire clinical spectrum of symptoms related to IBS-C."

IBS, an often painful disorder of the lower intestine, affects between 10 to 15 percent of the U.S. population.

While IBS is the second-leading cause of work absenteeism behind the common cold, Chey says fewer than half of patients with IBS seek medical treatment. And, he says, most over-the-counter medicines commonly used to treat symptoms -- fiber, laxatives and stool stimulants -- don't address the bloating and pain associated with IBS.

Most patients with IBS tend to fall into two categories: IBS-C or IBS with diarrhea. IBS-C is more common among older adults, while IBS-D tends to be seen more in younger patients.

Since the majority of patients with IBS are women, studies involving IBS tend to be made up of predominately female participants -- more than 80 percent in most cases, Chey estimates.

"Although AMITIZA is only approved for use in women with IBS-C, it doesn't mean that the drug doesn't work for men. Unfortunately, we just haven't had enough men represented in these studies to make a firm decision on treatment using this drug," notes Chey.

The supplemental New Drug Application for AMITIZA -- which also is approved by the FDA for treatment of chronic idiopathic constipation -- was based on two phase III, multi-center trials involving 1,154 participants. These trials compared lubiprostone versus a placebo during the course of 12 weeks. Each participant kept an electronic diary to report weekly outcomes of IBS-C symptoms.

After one week, 20 percent of the lubiprostone participants reported moderate to significant relief of symptoms. By week four, 32 percent said they experienced relief of global IBS-C symptoms -- abdominal pain, bloating, constipation severity and straining during bowel movements. Lubiprostone also improved stool consistency.

Additionally, Chey will present findings at DDW from a follow-on study related to the two phase III trials. This 48-week study looked at the efficacy and safety of lubiprostone. Many of its 476 participants also took part in the phase III trials. For this study, however, participants all received lubiprostone; no placebos were given.

The study found that lubiprostone is effective and well tolerated in adults with IBS-C for up to one year. The spectrum of symptoms that constitute IBS-C, including abdominal pain and discomfort, bloating and constipation-related complaints, significantly improved during the 48-week treatment period. The most common treatment-related adverse events among the study groups were nausea and diarrhea.


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Cite This Page:

University of Michigan Health System. "Drug Brings Relief For Many IBS Patients Who Experience Constipation." ScienceDaily. ScienceDaily, 20 May 2008. <www.sciencedaily.com/releases/2008/05/080519083028.htm>.
University of Michigan Health System. (2008, May 20). Drug Brings Relief For Many IBS Patients Who Experience Constipation. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2008/05/080519083028.htm
University of Michigan Health System. "Drug Brings Relief For Many IBS Patients Who Experience Constipation." ScienceDaily. www.sciencedaily.com/releases/2008/05/080519083028.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Ebola Virus Threatens West Africa

Deadly Ebola Virus Threatens West Africa

AP (July 28, 2014) — West African nations and international health organizations are working to contain the largest Ebola outbreak in history. It's one of the deadliest diseases known to man, but the CDC says it's unlikely to spread in the U.S. (July 28) Video provided by AP
Powered by NewsLook.com
$15B Deal on Vets' Health Care Reached

$15B Deal on Vets' Health Care Reached

AP (July 28, 2014) — A bipartisan deal to improve veterans health care would authorize at least $15 billion in emergency spending to fix a veterans program scandalized by long patient wait times and falsified records. (July 28) Video provided by AP
Powered by NewsLook.com
Two Americans Contract Ebola in Liberia

Two Americans Contract Ebola in Liberia

Reuters - US Online Video (July 28, 2014) — Two American aid workers in Liberia test positive for Ebola while working to combat the deadliest outbreak of the virus ever. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) — Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins